Atossa Therapeutics Statistics
Share Statistics
Atossa Therapeutics has 129.17M
shares outstanding. The number of shares has increased by 2.71%
in one year.
| Shares Outstanding | 129.17M |
| Shares Change (YoY) | 2.71% |
| Shares Change (QoQ) | 2.68% |
| Owned by Institutions (%) | 23.8% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 4,027 |
| FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 7.63M, so 5.9% of the outstanding
shares have been sold short.
| Short Interest | 7.63M |
| Short % of Shares Out | 5.9% |
| Short % of Float | 5.91% |
| Short Ratio (days to cover) | 9.59 |
Valuation Ratios
The PE ratio is -4.66 and the forward
PE ratio is -2.79.
Atossa Therapeutics's PEG ratio is
0.28.
| PE Ratio | -4.66 |
| Forward PE | -2.79 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 1.66 |
| P/FCF Ratio | -5.65 |
| PEG Ratio | 0.28 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Atossa Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.99,
with a Debt / Equity ratio of 0.
| Current Ratio | 14.99 |
| Quick Ratio | 14.99 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,700,266.67 |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -52.07% in the
last 52 weeks. The beta is 1.02, so Atossa Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | -52.07% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 1.09 |
| Relative Strength Index (RSI) | 56.97 |
| Average Volume (20 Days) | 616,309 |
Income Statement
| Revenue | n/a |
| Gross Profit | -17K |
| Operating Income | -27.62M |
| Net Income | -25.5M |
| EBITDA | -25.49M |
| EBIT | -25.5M |
| Earnings Per Share (EPS) | -0.2 |
Full Income StatementBalance Sheet
The company has 71.08M in cash and 0 in
debt, giving a net cash position of 71.08M.
| Cash & Cash Equivalents | 71.08M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -211.79M |
| Total Assets | 76.44M |
| Working Capital | 69.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -21.03M
and capital expenditures -19K, giving a free cash flow of -21.05M.
| Operating Cash Flow | -21.03M |
| Capital Expenditures | -19K |
| Free Cash Flow | -21.05M |
| FCF Per Share | -0.17 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
